Skip to content
etf.net

BBH

GradeBNASDAQ Global Market

VanEck Biotech ETF

Themes · VanEck · Inception 2011-12-20 · SEC filings

$239.67−2.36 (−0.98%)

As of Sep 23, 2026, 2:20 PM EDT

Intraday session: down, 59 prints from 242.03 to 239.67. Range 239.48 to 243.88. Use the arrow keys to read each point.$242.00$244.0010 AM12 PM2 PM4 PM
Expense ratio
0.35%
Fund size
$477M
1Y return
+45.3%
Yield · Last 12 months
0.40%
Holdings
25
Volume · 30D
0M sh
NAV per share
$237.51
52W range
low $160.91high $244.35

The ETF.net BBH Grade

B

67/ 100

Rank 5 of 17 in Biotech & Genomics⁠

Confidence Medium

Six-pillar profile for BBH. Scores out of 100: Cost 81, Risk 62, Mission not scored, Tradability 70, Holdings 28, Durability 69. Strongest: Cost (81). Weakest: Holdings (28). Based on 5 of 6 pillars.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 67 of 100 sits in the B band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    AScore 81
    Category rank3/17 · top 18%

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    Not scored
    —

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    BScore 62
    Category rank5/17 · top 29%

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    AScore 70
    Category rank5/17 · top 29%

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    DScore 28
    Category rank17/17 · bottom quartile

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    BScore 69
    Category rank6/17 · top 35%

Graded as of Sep 22, 2026 · Based on 5 of 6 pillars

Our read on BBH

ETF.net Research

BBiotech, distilled. BBH tracks an index of around 25 US-listed drug and diagnostics companies, so each name carries real weight instead of getting lost in a crowd. Running since 2011, at a fee below the typical biotech fund.

Stated mandate

The fund seeks to track, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. That index represents companies involved in developing, producing, marketing, and selling drugs based on genetic analysis and diagnostic equipment.

Why people hold it

  1. 010.35% a year, below the 0.50% typical for biotech funds and level with XBI.
  2. 02Around 25 holdings, so the leaders in the index actually move the fund rather than getting diluted across hundreds of tickers.
  3. 03Rules-based: it follows the MVIS US Listed Biotech 25 Index, no manager guessing which drug pipeline pans out.vaneck.com
  4. 04Trading since 2011, through several full biotech cycles, and it sits in the upper half of its biotech peer group.

Worth knowing

  1. 01Concentration cuts both ways: with roughly 25 names, one failed trial or patent cliff lands hard.
  2. 02One of the less-traded funds in the biotech aisle, so bid-ask spreads deserve attention. Limit orders are the usual fix.
  3. 03Not the cheapest seat in the category: IBBQ charges 0.19%.

BBH Holdings

As of Sep 20, 2026, 6:07 AM
Asset class
Stocks
Holdings
25
Top-10 weight
72%
Largest holding
AMGN13.7%

Sectors

  • Health Care100.0%

Geography

  • United States88.00%
  • Netherlands5.63%
  • Switzerland3.00%
  • Germany1.77%
  • Ireland1.60%
The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001AMGNAmgen Inc13.74%180,275$68M470
002GILDGilead Sciences Inc13.12%433,284$65M482
003VRTXVertex Pharmaceuticals Inc8.13%78,450$41M417
004REGNRegeneron Pharmaceuticals Inc6.75%42,633$34M401
005MRNAModerna Inc6.52%205,580$32M240
006NTRANatera Inc5.70%77,578$28M223
007IQVIqvia Holdings Inc5.16%95,418$26M290
008RVMDRevolution Medicines Inc4.76%120,546$24M169
009ARGXArgenx Se4.58%22,942$23M68
010ILMNIllumina Inc3.80%77,203$19M305
011BIIBBiogen Inc3.16%71,860$16M331
012ONCBeone Medicines Ltd2.99%42,209$15M35
013ALNYAlnylam Pharmaceuticals Inc2.69%54,502$13M258
014INSMInsmed Inc2.67%107,202$13M183
015INCYIncyte Corp2.41%94,098$12M364

Showing 1–15 of 26 holdings

BBH Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBH$14,527
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. BBH $14,527. SPY $11,723. Use the arrow keys to read each point.$9,122$12,089$15,056Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBH. Periods over one year show the average yearly return.
PeriodBBH
Year to date+27.9%
1 month+0.3%
3 months+27.8%
1 year+45.3%
3 years+16.5%per year
5 years+2.8%per year
10 years+7.8%per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBH
YearReturn barBBH
2026 YTD+27.9%
2025+21.2%
2024−4.3%
2023+3.9%
2022−15.2%
2021+11.8%
2020+22.1%

BBH in the news

BBH Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
0.40%Last 12 months
Payout per share
$0.96Last 12 months
Last payment
$0.96 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Annual

Distribution history

2017–2026

One bar per payment. 9 payments from 2017 to 2026 YTD. Dec 18, 2017 $0.68; Dec 20, 2018 $0.55; Dec 23, 2019 $0.47; Dec 21, 2020 $0.61; Dec 20, 2021 $0.40; Dec 19, 2022 $0.75; Dec 18, 2023 $0.71; Dec 23, 2024 $1.25; Dec 22, 2025 $0.96. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 22, 2025Dec 26, 2025$0.96
Dec 23, 2024Dec 24, 2024$1.25
Dec 18, 2023Dec 22, 2023$0.71
Dec 19, 2022Dec 23, 2022$0.75
Dec 20, 2021Dec 27, 2021$0.40
Dec 21, 2020Dec 28, 2020$0.61
Dec 23, 2019Dec 30, 2019$0.47
Dec 20, 2018Dec 27, 2018$0.55
Dec 18, 2017Dec 22, 2017$0.68
Dec 19, 2016Dec 23, 2016$0.33
Dec 21, 2015Dec 28, 2015$0.34
Dec 23, 2013Dec 30, 2013$0.003

BBH Risk

How much the fund’s monthly returns vary, scaled to a year.
18.1%
Annualised · 36 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.55
vs 3-month T-bills · to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−39.3%
Trough Jun 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.56
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

BBH Cost

Expense ratio0.35%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

1 of the 15 Biotech & Genomics funds charge less.

BBH costs $35.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.